Home
About
Overview
Sharing Data
ORCID
Help
History (16)
Restricting a-synuclein transport into mitochondria by inhibition of a-synuclein-VDAC complexation as a potential therapeutic target for Parkinson's disease treatment.
Phosphotungstic Acid
Constellation of risks and processes seen in search for Alzheimer's clues.
Influenza A Virus, H1N1 Subtype
Risks and benefits associated with novel phase 1 oncology trial designs.
See All 16 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Risks and benefits associated with novel phase 1 oncology trial designs.
Risks and benefits associated with novel phase 1 oncology trial designs. Cancer. 2007 Sep 01; 110(5):1115-24.
View in:
PubMed
subject areas
Antineoplastic Agents
Clinical Trials, Phase I as Topic
Dose-Response Relationship, Drug
Humans
Neoplasms
Risk Assessment
Treatment Outcome
authors with profiles
Elizabeth Garrett Garrett-Mayer